SC Therapeutics has initiated the randomized, double-blind, placebo-controlled Phase II REACH2 study of SC0032, an investigational magnesium salt laryngeal soft-mist spray, in adults with refractory or unexplained chronic cough. The three-centre UK study will assess whether three weeks of four-times-daily treatment can reduce 24-hour cough frequency and whether any benefit persists during a four-week period without treatment.
Why does REACH2 represent a more credible test than the earlier chronic cough study?
The importance of REACH2 lies less in the start of another early-stage trial and more in how its design attempts to resolve the weaknesses of SC Therapeutics’ previous evidence. Earlier work with a related spray formulation produced an encouraging signal, including a reported placebo-adjusted reduction in cough frequency and observations suggesting that suppression continued after dosing ended. However, those findings came from a very small study in which the crossover design was affected by a treatment-period effect, forcing the primary efficacy assessment to rely on the first treatment period as a parallel comparison.
That earlier dataset was therefore hypothesis-generating rather than confirmatory. The intention-to-treat population included only 10 participants, the per-protocol analysis involved seven, and a statistically significant post hoc adherence analysis was based on six participants. Results from groups that small can be disproportionately influenced by individual responses, adherence patterns, baseline severity and regression toward the mean. They can identify a potentially valuable signal, but they cannot establish the magnitude, consistency or commercial relevance of an effect.
REACH2 moves to a parallel-arm structure, removing the carryover problem that complicated interpretation of the previous crossover study. Participants will complete a two-week placebo run-in before randomization, followed by three weeks of SC0032 or placebo and four weeks of observation without treatment. That design should produce a cleaner comparison between groups while allowing investigators to examine onset, treatment-period efficacy and durability separately.
The unresolved issue is statistical power. The public registry describes REACH2 as a pilot study but does not state a planned enrolment figure. A well-controlled design can improve evidence quality, but a small sample may still generate wide confidence intervals and subgroup imbalances. Positive results would strengthen the rationale for a larger pivotal programme, although they would not automatically provide definitive evidence of clinical efficacy.
Can seven-day cough monitoring solve variability without creating new measurement risks?
Refractory chronic cough presents an unusually difficult measurement problem because cough frequency can change substantially from one day to the next. Environmental exposure, speaking, sleep, hydration, stress and respiratory irritation can all influence coughing. A treatment may therefore appear effective or ineffective depending on which day is selected for assessment, particularly when studies rely on short recording windows.
REACH2 will compare seven continuous days of objective monitoring near the end of the baseline period with seven days near the end of treatment. This is a meaningful methodological upgrade because longer observation should reduce the influence of an unusually good or bad day. Continuous monitoring may also reveal whether improvement is stable, gradual or concentrated at particular times, providing more useful information than a single averaged endpoint.
The study will use the Hyfe cough-monitoring platform to measure 24-hour cough frequency and cough-bout characteristics. This digital layer could help SC Therapeutics identify time to response, duration of response, changes in bout length and differences between rapid cough suppression and slower improvement in laryngeal hypersensitivity. Patient-reported measures covering cough severity, quality of life, perceived change and laryngeal symptoms will provide a second perspective on whether numerical cough reduction translates into a benefit that patients can feel.
Digital monitoring also introduces its own risks. Cough-detection algorithms must distinguish genuine coughs from speech, throat clearing, background noise and coughing by other people. The exclusion of participants living with someone who has chronic cough, along with restrictions involving excessively noisy workplaces, shows how dependent the study is on measurement integrity. Device wear time, battery management, app use and missing recordings could further affect data quality.
Regulators evaluating chronic cough programmes have previously examined whether cough-counting systems are sufficiently validated and whether statistically significant reductions are clinically meaningful. REACH2 will therefore need to demonstrate more than a favourable algorithm-generated percentage. Concordance between objective frequency, patient-reported severity, quality of life and global improvement will be critical.
Why is the four-week off-treatment period central to the disease-modifying claim?
SC Therapeutics is positioning SC0032 as an upstream intervention rather than another therapy that temporarily suppresses neural cough signalling. The proposed mechanism involves delivering an alkaline magnesium salt mist to rehydrate the laryngeal and proximal airway surface, reduce local irritation and relieve abnormal mechanical pressure affecting mechano-sensitive ion channels. The hypothesis is that normalising the airway environment could reduce the hypersensitive cough response at its source.
This is a scientifically differentiated proposition, but disease modification remains an unproven interpretation. A treatment can produce an effect that lasts after the final dose without permanently altering the underlying disease process. Residual physiological effects, behavioural adaptation, fluctuating exposure to irritants or natural variation in cough frequency could all produce apparent persistence.
The four-week untreated follow-up is consequently the most strategically important part of REACH2. A clear separation from placebo that continues after SC0032 has been discontinued would support the argument that the treatment is doing more than providing immediate surface soothing. The strength of that conclusion would increase if durability were accompanied by improvement in laryngeal hypersensitivity, cough-bout behaviour and patient-reported quality of life.
REACH2 does not appear to include a direct mechanistic biomarker capable of confirming that mechano-sensitive ion channels have been downregulated or that airway hydration has been durably restored. The trial can establish a clinical pattern consistent with the proposed mechanism, but it may not prove the biological pathway responsible for that pattern. Future development could require physiological, imaging or biomarker evidence to support stronger disease-modifying language.
How does SC0032 compare with P2X3 antagonists and current chronic cough management?
The most advanced targeted therapies in refractory chronic cough have focused on P2X3 receptors involved in sensory nerve activation. Gefapixant has secured approval in Europe for refractory or unexplained chronic cough, providing validation that cough hypersensitivity can be treated through receptor-directed pharmacology. Its development has also illustrated the field’s challenges, including taste-related adverse effects and debate over whether reductions in cough frequency are large enough to be clinically meaningful.
GSK is developing the more selective P2X3 antagonist camlipixant in Phase III studies, with pivotal readouts expected during 2026. Greater receptor selectivity is intended to preserve efficacy while reducing taste disturbance associated with less selective inhibition. Those results could establish a new competitive benchmark before SC0032 reaches later-stage development.
SC0032 is not attempting to compete as another receptor-blocking tablet. Its differentiation rests on local delivery, an endogenous-ion formulation and a proposed effect on the airway conditions that contribute to hypersensitivity. That could create a favourable tolerability profile and allow use either independently or alongside neural-pathway therapies. It could also make SC0032 relevant to patients who do not respond to P2X3 antagonism or cannot tolerate systemic treatment.
The comparison remains theoretical until REACH2 produces stronger evidence. Oral medicines are familiar, easy to prescribe and straightforward for patients to carry. SC0032 requires four puffs four times daily during the study, creating a greater adherence burden. A local spray would need either superior tolerability, a meaningful efficacy advantage or less frequent maintenance dosing to offset that inconvenience.
Current management can also include treatment of underlying conditions, specialist cough-control therapy and off-label neuromodulators such as gabapentin or pregabalin. These approaches can help selected patients but may be limited by inconsistent responses, access to specialist services or systemic side effects. SC0032 could occupy a valuable middle ground if it combines device-like safety with pharmacologically meaningful efficacy, but REACH2 must first show that the effect is reproducible rather than formulation-specific or study-specific.
Could device classification accelerate development while complicating global regulation?
The REACH2 registry classifies SC0032 as an investigational medical device and describes the intervention as a magnesium salt oral spray. This matters because SC Therapeutics presents itself as a clinical-stage biopharmaceutical developer, while the programme’s formal clinical framework is based on medical-device standards rather than a conventional drug-development pathway.
A device-led route may offer strategic advantages if the product’s principal action is considered physical or physicochemical rather than pharmacological. The formulation uses salts naturally present in human airways, and the delivery concept focuses on surface hydration and modulation of the local airway environment. That could support a relatively favourable safety proposition and potentially simplify some elements of systemic toxicology development.
However, classification is not automatically consistent across jurisdictions. Regulators may reach different conclusions about whether the primary mode of action is physical, pharmacological or a combination of both. The product also depends on the interaction between formulation and delivery hardware, requiring evidence that aerosol characteristics, dose uniformity and clinical performance remain consistent.
The commercial regulatory strategy will need to become clearer if REACH2 succeeds. SC Therapeutics may face different evidence requirements in the United Kingdom, European Union and United States, particularly if future claims extend beyond temporary symptom relief to disease modification. A device pathway can be efficient, but ambitious therapeutic claims generally require correspondingly strong clinical evidence.
What adherence, usability and manufacturing barriers could constrain a soft-mist spray?
SC0032’s four-times-daily dosing schedule is manageable within a supervised clinical trial but may be challenging in routine care. Patients with chronic cough already experience sleep disruption, fatigue and interference with work or social activities. Requiring repeated dosing throughout the day could reduce real-world adherence, particularly if improvement is gradual rather than immediately perceptible.
The optional usability component in REACH2 is therefore commercially relevant rather than merely operational. Spray technique, mouth positioning, inhalation behaviour and device handling could influence where the mist is deposited and how consistently the dose reaches the laryngeal region. A therapy with a narrow technique requirement may perform differently outside specialist cough centres.
Durable post-treatment activity could change this calculation. If patients can transition from frequent initial dosing to intermittent maintenance, the treatment could become considerably more convenient. REACH2’s follow-up may indicate whether that possibility deserves formal testing, but it cannot establish an optimal long-term regimen on its own.
Manufacturing will also involve more than mixing an inexpensive salt solution. SC Therapeutics will need to control concentration, stability, microbiological quality, aerosol plume, droplet distribution and dose reproducibility across batches and devices. The current SC0032 version is intended to improve formulation stability and oral delivery reliability compared with earlier spray versions, but those improvements must be demonstrated at commercial scale.
Which REACH2 outcomes will determine whether SC Therapeutics has a scalable platform?
The first threshold will be a credible placebo-adjusted reduction in 24-hour cough frequency across the full randomized population. The magnitude of that reduction, confidence intervals, missing-data handling and consistency across study centres will matter more than a favourable percentage viewed in isolation.
The second threshold will be alignment between objective and subjective outcomes. A therapy that lowers machine-counted coughs without improving severity, quality of life or patient-perceived change may struggle to convince clinicians, regulators or payers. Conversely, moderate frequency reduction accompanied by meaningful functional improvement could support a more persuasive value proposition.
The third threshold will be durability. Persistent separation during the four-week untreated period would provide the strongest evidence for SC Therapeutics’ upstream biological thesis. Rapid loss of benefit after dosing stops would not necessarily make SC0032 ineffective, but it would reposition the spray as a symptomatic treatment and weaken the proposed distinction from receptor-directed therapies.
Safety and usability will remain essential. Local irritation, bronchospasm, unpleasant taste, treatment discontinuations or poor adherence could offset the perceived advantages of an endogenous-ion formulation. A clean safety profile combined with consistent device use would strengthen the case for larger studies and potential combination approaches.
SC Therapeutics is also seeking to build a broader platform around mechano-sensitive ion channels in respiratory and cardiovascular conditions. REACH2 will therefore test more than one chronic cough product. It will indicate whether airway-surface modulation can produce a clinically measurable, durable and scalable therapeutic effect. Positive pilot results would justify a larger confirmatory programme, but the real inflection point will come only when the mechanism survives testing in a sufficiently powered population and produces benefits patients recognise beyond the monitoring device.
